Trusted Resource for Clinical Trials, Protocols & Progress
During the lifecycle of drug or device development, regulatory agencies such as the U.S. FDA, European Medicines Agency (EMA), and Japan’s PMDA often send communications that include questions, comments, or observations. These queries may arise in response to:
Click to read the full article.
Drug development and approval processes are rarely linear. After an initial submission—be it an IND, NDA, BLA, or CTA—sponsors often receive a first round of questions from regulators. However, this may not be the end. Agencies like the FDA, EMA, and PMDA frequently issue multiple rounds of feedback, especially for complex or novel therapies.
Click to read the full article.
Gaining marketing authorization is a critical milestone in the lifecycle of a drug or biologic. However, it does not mark the end of regulatory scrutiny. Post-approval commitments (PACs)—which include post-marketing requirements (PMRs) and post-marketing commitments (PMCs)—are essential mechanisms used by health authorities to continue assessing the safety, efficacy, and quality of approved products.
Click to read the full article.
Approval of a drug or biologic does not eliminate the need for ongoing safety monitoring. Post‑marketing safety studies are designed to detect rare adverse events, assess long-term safety, and evaluate real‑world effectiveness. Regulatory authorities such as the FDA, EMA, PMDA, and Health Canada often require these studies as commitments or conditions of approval to protect public health.
Click to read the full article.
After approval, many products are subject to post‑approval study obligations—such as Post-Marketing Requirements (PMRs) in the U.S., or Post-Authorization Safety Studies (PASS) in Europe. Sponsors must submit **annual reports** to health authorities to update on the status, progress, and findings of these studies. These reports maintain compliance, demonstrate continued commitment to safety, and frequently influence future regulatory decisions.
Click to read the full article.
Once a drug receives FDA approval, maintaining up-to-date and compliant documentation for any manufacturing, labeling, or quality changes is essential. The FDA provides two key mechanisms for implementing such changes in the U.S. regulatory framework:
Click to read the full article.
Product labeling is a living document that guides clinical use, informs patients, and serves as a legal reference for healthcare professionals. Following regulatory approval, labeling must be continually managed to reflect new safety information, updated usage guidance, pediatric expansions, and risk mitigation strategies. Failure to keep labeling compliant can lead to safety issues, regulatory citations, or loss of approval.
Click to read the full article.
Traditional randomized controlled trials (RCTs) often leave key evidence gaps at approval—especially regarding long-term safety, effectiveness in broader populations, and rare adverse events. Real‑World Evidence (RWE), derived from Real‑World Data (RWD) such as electronic health records, claims databases, and patient registries, is increasingly leveraged post-approval to bridge these gaps in a pragmatic, scalable way. It is being integrated into Post-Marketing Requirements (PMRs) and Commitments (PMCs) to fulfill regulatory expectations with high relevance to everyday clinical practice.
Click to read the full article.
After a drug or biologic gains regulatory approval, its journey is far from over. Regulators often impose post‑approval commitments—studies designed to confirm long-term safety, effectiveness, and risk mitigation strategies in the real-world population. While randomized controlled trials (RCTs) have long been the gold standard, they can be expensive, time-consuming, and less reflective of real-world conditions.
Click to read the full article.
After a product has been approved and launched, regulatory expectations do not end—the communication of post‑approval changes becomes crucial. These modifications may include updates to labeling, safety monitoring measures, manufacturing, packaging, or indications. Informing stakeholders such as health authorities, healthcare providers, patients, field teams, and internal departments is essential for ensuring safe use, maintaining regulatory compliance, and preserving trust.
Click to read the full article.
